Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trilogy International Partners Inc T.TRL.WT.A


Primary Symbol: V.TRL.H

Trilogy International Partners Inc. operates through its subsidiary Trilogy International Partners LLC (Trilogy LLC). Prior to the disposal of its New Zealand and Bolivia operations, Trilogy LLC was a provider of wireless voice and data communications services including local, international long distance and roaming services. Trilogy LLC also provided fixed broadband communications services to residential and enterprise customers in New Zealand and Bolivia. The Company had two reportable segments identified by their geographic regions, New Zealand and Bolivia. Two Degrees Mobile Limited (2degrees) operated in New Zealand and Empresa de Telecomunicaciones NuevaTel (PCS de Bolivia), S.A. (NuevaTel) operated in Bolivia. Both these segments provided a variety of wireless voice and data communications services, including local, international long distance and roaming services. The services were provided to subscribers on both a postpaid and prepaid basis.


TSXV:TRL.H - Post by User

Post by LTOWNERon Mar 09, 2014 12:33pm
213 Views
Post# 22299781

FDA’s Willingness To Approve Another TRT Drug

FDA’s Willingness To Approve Another TRT DrugAVEED’s approval last Thursday answers the question as to whether the FDA is willing to approve a TRT drug while in the process of investigating recent negative TRT research reports: YES!
 
I also cannot help but think Compleo should be a shoe-in for approval after reading the life-threatening side effects of AVEED!  Oil embolism in the lung, life-threatening allergic reaction, the need to stay 30 minutes after injection, possible need for emergency treatment in hospital up to 24 hours after injection.  This medication will only be available through a very restricted program.  No thank you!
 
Sepper, I have no idea where the stock will trade tomorrow or in the coming weeks as the company gets closer to approval and Tefina results.  But it is unlikely to trade down based on its 2013 annual loss.  This is a drug development company with no revenues to date.  The loss was expected.

Bullboard Posts